Avidity Biosciences (RNA) announced the FDA has removed the partial clinical hold on delpacibart etedesiran, an investigational treatment designed to address the root cause of myotonic dystrophy type 1. Del-desiran is being evaluated in the Phase 3 HARBOR trial in patients with dystrophy type 1.
Del-desiran or AOC 1001, Avidity's lead product candidate utilizing its AOC platform, is designed to address the root cause of dystrophy type 1 by reducing levels of a disease-related mRNA called DMPK. Del-desiran has received Breakthrough Therapy, Orphan Drug and Fast Track designations by the FDA and Orphan designation by the European Medicines Agency.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.